The estimated Net Worth of Andrew Paul Mazar is at least $533 Tysiąc dollars as of 31 March 2022. Dr Mazar owns over 1,606 units of Monopar Therapeutics Inc stock worth over $54,228 and over the last 5 years he sold MNPR stock worth over $0. In addition, he makes $479,008 as Exec. VP of R&D i Chief Scientific Officer and Director at Monopar Therapeutics Inc.
Dr has made over 6 trades of the Monopar Therapeutics Inc stock since 2021, according to the Form 4 filled with the SEC. Most recently he exercised 1,606 units of MNPR stock worth $3,854 on 31 March 2022.
The largest trade he's ever made was exercising 3,212 units of Monopar Therapeutics Inc stock on 30 June 2021 worth over $7,709. On average, Dr trades about 1,323 units every 50 days since 2020. As of 31 March 2022 he still owns at least 22,595 units of Monopar Therapeutics Inc stock.
You can see the complete history of Dr Mazar stock trades at the bottom of the page.
Dr. Andrew P. Mazar is the Exec. VP of R&D, Chief Scientific Officer and Director at Monopar Therapeutics Inc.
As the Exec. VP of R&D i Chief Scientific Officer and Director of Monopar Therapeutics Inc, the total compensation of Dr Mazar at Monopar Therapeutics Inc is $479,008. There are 1 executives at Monopar Therapeutics Inc getting paid more, with Dr. Chandler D. Robinson M.B.A., M.Sc., MBA, M.D., MSc having the highest compensation of $602,888.
Dr Mazar is 59, he's been the Exec. VP of R&D i Chief Scientific Officer and Director of Monopar Therapeutics Inc since . There are 2 older and 4 younger executives at Monopar Therapeutics Inc. The oldest executive at Monopar Therapeutics Inc is Dr. Patrice P. Rioux M.D., Ph.D., 70, who is the Acting Chief Medical Officer.
Andrew's mailing address filed with the SEC is 1000 SKOKIE BLVD STE 350, , WILLMETTE, IL, 60091.
Over the last 5 years, insiders at Monopar Therapeutics Inc have traded over $1,830,000 worth of Monopar Therapeutics Inc stock and bought 895,199 units worth $6,154,669 . The most active insiders traders include Michael J Brown, Diane Hendricks oraz Pharma Llc Mazar Andrew Pau.... On average, Monopar Therapeutics Inc executives and independent directors trade stock every 15 days with the average trade being worth of $32,266. The most recent stock trade was executed by Andrew Cittadine on 30 June 2024, trading 8,952 units of MNPR stock currently worth $21,485.
monopar therapeutics inc., a biopharmaceutical company, engages in developing proprietary therapeutics to enhance clinical outcomes for cancer patients in the united states. it is involved in developing validive, a clonidine mucobuccal tablet that is in phase iii for the treatment of radiation induced severe oral mucositis in oropharyngeal cancer patients; camsirubicin, a topoisomerase ii-alpha targeted analog of doxorubicin engineered to retain anticancer activity and for minimizing toxic effects on the heart; and mnpr-101, a humanized monoclonal antibody for treating advanced solid cancers. the company has a collaboration grupo espaã±ol de investigaciã³n en sarcomas for the development of camsirubicin in patients with advanced soft tissue sarcoma; and northstar medical radioisotopes, llc to develop radio-immuno-therapeutics targeting severe covid-19. monopar therapeutics inc. was founded in 2014 and is headquartered in wilmette, illinois.
Monopar Therapeutics Inc executives and other stock owners filed with the SEC include: